Gilead Defends Growth Prospects As Veklury Sales Drive Q3 Revenue Surge
Guidance Lowered For Sales Excluding The COVID-19 Drug
Third quarter revenue rose 13% year-over year to $7.4bn but fell 3% without Veklury to $5.4bn as the HCV and HIV franchises felt continued pandemic and generics impacts.
